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Abstract
Objective—The authors tested for genetic linkage of DSM-IV-diagnosed major depressive
disorder in families that were ascertained for cigarette smoking.
Method—Within a study that targeted families characterized by a history of smoking, analyses
derived a subset of 91 Australian families with two or more offspring with a history of DSM-IV
major depressive disorder (affected sibling pairs, N=187) and 25 Finnish families (affected sibling
pairs, N=33). Within this affected sibling pair design, the authors conducted nonparametric
linkage analysis.
Results—In the Australian heavy smoking families, the authors found a genome-wide significant
multipoint LOD score of 4.14 for major depressive disorder on chromosome 3 at 24.9 cM
(3p26-3p25).
Conclusions—Genome-wide significant linkage was detected for major depressive disorder on
chromosome 3p in a sample ascertained for smoking. A linkage peak at this location was also
observed in an independent study of major depressive disorder.
Introduction
Genetic linkage studies of major depressive disorder have found suggestive evidence across
multiple genomic regions with little convergence of findings 1. Genetic association,
including genomewide association studies (GWAS), findings have been similarly
disparate 2–7. These inconsistencies raise the question of whether major depressive disorder
encompasses a number of poorly understood subtypes (e.g., depression in smokers). Among
smokers seeking cessation treatment, lifetime rates of major depression have been estimated
at over 60%8. Cigarette smokers with a history of depression tend to report more severe
nicotine withdrawal symptoms 9–11, are more likely to relapse to smoking after a quit
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attempt8, and may be at increased risk for a recurrent episode of depression after smoking
cessation12. Models describing the relationship between symptoms of depression and
smoking include examples of shared genetic risk13. We carried out genetic linkage analyses
of DSM-IV diagnosed major depressive disorder in two samples that are part of the Nicotine
Addiction Genetics project14;15, an international consortium focused on tobacco
dependence. We used an affected sibling pair design, in which at least two adult offspring
per family reported a history of DSM-IV major depressive disorder, and tested for linkage.
Results appear to confirm a genome-wide significant linkage signal at 3p26-3p25, also
reported in an independent linkage study of major depressive disorder16.
Method
Samples
The Nicotine Addiction Genetics linkage project enrolled participants at the Queensland
Institute of Medical Research in Australia and the University of Helsinki in Finland. Both
sites utilized twin registries and targeted families of index cases who previously reported a
history of cigarette smoking in interview or questionnaire surveys; the Australian site using
a higher threshold measure when recruiting index cases with a history of heavy smoking14.
These original linkage samples included microsatellite marker data and telephone diagnostic
interviews in 289 families from the Australian site (offspring, N=917; parents, N=392) and
161 families from the Finnish site (offspring, N=522; parents, N=19). More than 90% of the
participants from the Australian site were of Anglo-Celtic or Northern European ancestry,
and all of the participants from the Finnish site were of Finnish ancestry. The assessment
included a diagnostic telephone interview, adapted from the Semi-Structured Assessment for
the Genetics of Alcoholism17;18, which obtained a comprehensive assessment of lifetime
DSM-IV19 major depressive disorder as well as a tobacco use and dependence assessment
derived from the Composite International Diagnostic Interview20. Additional details on the
original samples and assessments have been described elsewhere 14;15;21. For the present
study, we conducted genetic linkage analyses using the 91 Australian families who had one
or more affected sibling pairs concordant for history of major depressive disorder (N=187).
In the Finnish sample, only 25 families had one or more affected sibling pairs (N=33), and
thus the primary analyses focused on the Australian sample. A summary of the two major
depressive disorder linkage samples is presented in Table 1 of the data supplement.
Analyses
For both the Australian and Finnish samples, 381 autosomal microsatellite markers were
genotyped and spaced at approximately 10 cM across the genome, positioned using the
deCODE genetic map22. Details of genotyping, including quality control procedures are
described elsewhere14,15. Single- and multi-point affected sibling pair nonparametric linkage
(the latter using a 2 cM grid) was conducted in MERLIN (Multipoint Engine for Rapid
Likelihood Inference)23, which generated LOD scores 24, 25. Upon detection of LOD scores
> 3, genome-wide corrected p values were calculated from 1,000 replicates simulated in
MERLIN26;27.
Follow-up fine mapping included the addition of 290 single nucleotide polymorphism
(SNPs) on chromosome 3 that were available for a portion of the Australian major
depressive disorder linkage sample (84 out of 91 families), from other Australian projects
with overlapping samples that have obtained GWAS data (see reference 28). Through the use
of Snagger software 29, these SNPs were selected to be in low linkage disequilibrium
(maximum pairwise r2= 0.2), to have a minor allele frequency > 40%, and to have a
minimum distance between two tags of 450 kb in order to optimize information content.
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For the Australian linkage sample, a multipoint LOD of 4.14 for major depressive disorder
was found on chromosome 3 (at 24.9 cM). The highest single-point linkage signal emerged
at microsatellite marker D3S1304, with a LOD score of 3.7. The LOD of 4.14 at 3p in this
sample met genomewide significance (p = 0.004). A complete report of these single- and
multipoint findings, along with marker positions by chromosome, is provided in Table 2 of
the data supplement. The addition of 290 SNPs on chromosome 3 narrowed the linkage
locus and increased the LOD score to 4.55 (at 25.3 cM) (see Figure 1). For the Finnish
major depressive disorder sample, a multipoint LOD score of 2.10 was found on
chromosome 20 (at 90.9 cM).
Given that no linkage signals over 1.5 overlapped across both samples, we did not conduct a
combined analysis. However, if we were to correct conservatively for testing in both
samples by doubling the p value generated from the 1,000 simulations, we would still
maintain a genomewide significant p value of 0.008.
Discussion
Overall, major depressive disorder was associated with a significant genetic linkage peak (a
LOD score of 4.14) on chromosome 3 in the Nicotine Addiction Genetics Australian sample,
replicating the linkage reported at the same location by Breen et al 16. These converging
findings suggest that the genomic region spanning 3p26-3p25 is an important area for
further investigation in genetic research on major depressive disorder. Given the small
number of Finnish affected sibling pairs, the lack of confirmation in this particular sample is
not unexpected. The genetic variants accounting for this linkage signal have not yet been
convincingly identified. Although our highest single-point microsatellite marker (D3S1304
[LOD score =3.7]) lies within the metabotropic glutamate receptor 7 gene (GRM7),
subsidiary association analyses within a one-LOD support interval, using GWAS data
available in the Australian sample (28), found only nominal association for two SNPs within
GRM7 (p < .05). Even our strongest association effect, with was a p value of 0.00014 for
rs6765537 (a nonsynonymous SNP within C3or20 at 33.87 cM), did not replicate in the
Finnish families, nor did it replicate in the Genetic Association Information Network major
depressive disorder sample from the Netherlands30, 2. Thus, while others have found
suggestive association between SNPs in GRM7 and Major Depressive Disorder (7;31),
genome-wide significant effects have not been reported. Further, because linkage implicates
very broad regions, GRM7 is among many genes that might be hypothesized to explain our
signal.
In terms of other linkage findings, one for quantity smoked in samples ascertained for
depression has been reported near our chromosome 3 finding for major depressive
disorder 32, raising the possibility of common genetic influences across major depressive
disorder and smoking-related behavior or of gene-by-environment (i.e., smoking) interaction
effects on major depressive disorder.
There are important limitations associated with our results. Our sample of 91 families is
small by standards of modern genomic efforts. Thus, we cannot exclude the possibility that
our finding is a false positive that coincidentally appears to replicate Breen et al.16, whose
sample is much larger (> 800 families). Additionally, our finding at 3p26-3p25 (highest peak
at 24.9 cm) does not align with the meta-analyses results reported by McMahon et al.33, who
suggest that variants located at 3p21.1 (at approximately 70–72 cM) are associated with
mood disorders. Our future efforts to localize the genetic variants influencing major
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depressive disorder will entail confirmatory analyses in other samples and additional
genotyping in this region on 3p.
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Refer to Web version on PubMed Central for supplementary material.
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Chromosome 3: DSM-IV Major Depression NAG Australian sample; the LOD of 4.14
meets genome-wide significance at p = 0.004 with 1000 simulations in MERLIN;
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